Pharmacokinetic Interaction between Rifampin and the Combination of Indinavir and Low-Dose Ritonavir in HIV-Infected Patients

Justesen, U. S.; Andersen, Å. B.; Klitgaard, N. A.; Br∅sen, K.; Gerstoft, J.; Petersen, C.
February 2004
Clinical Infectious Diseases;2/1/2004, Vol. 38 Issue 3, p426
Academic Journal
Rifampin is an important drug in the treatment of tuberculosis, but administration of rifampin in combination with protease inhibitors is complicated because of drug-drug interactions. A prospective, controlled, multiple-dose study involving 6 HIV-infected patients receiving a combination of indinavir (800 mg) and ritonavir (100 mg) twice a day was performed to evaluate whether the inducing effect of rifampin on the drug-metabolizing enzyme cytochrome P450 (CYP) 3A4 could be overcome by the inhibitory effect of ritonavir. Pharmacokinetic evaluations of steady-state concentrations of indinavir and ritonavir were performed before and after administration of rifampin (300 mg every day for 4 days). An 87% reduction (from 837 to 112 ng/mL) in median indinavir and a 94% reduction (from 431 to 27 ng/mL) in median ritonavir concentrations were seen 12 h after the last dose of rifampin was administered (P=.031). These results strongly indicate that the administration of rifampin with a combination of indinavir (800 mg) and ritonavir (100 mg) could lead to subtherapeutic concentrations of indinavir.


Related Articles

  • New Protease Inhibitor Atazanavir (Reyatazâ„¢) Approved.  // AIDS Treatment News;6/27/2003, Issue 392, p3 

    Reports that the United States Food and Drug Administration (FDA) has approved the Atanazavir protease inhibitor. Press release issued by the drug's maker, Bristol-Myers Squibb.

  • New Protease Inhibitor Allows Once-Daily Dosing.  // RN;Aug2003, Vol. 66 Issue 8, p94 

    Announces the availability of once- and twice-daily dosing of the protease inhibitor, atazanavir sulfate. Effectiveness of the drug on patients under antiretroviral therapy.

  • indinavir:. Huber, Jeffrey T.; Gillaspy, Mary L. // Encyclopedic Dictionary of AIDS-Related Terminology;2000, p119 

    An encyclopedia entry for indinavir is presented, which refers to an HIV protease inhibitor that appears to have good oral bioavailability.

  • nelfinavir:. Huber, Jeffrey T.; Gillaspy, Mary L. // Encyclopedic Dictionary of AIDS-Related Terminology;2000, p160 

    This article presents an encyclopedia entry for "nelfinavir," which refers to an HIV protease inhibitor.

  • Tipranavir: A Viewpoint by Joel Gallant. Gallant, Joel // Drugs;2003, Vol. 63 Issue 15, p1619 

    Discusses the resistance profile of Tipranavir, a non-peptide inhibitor of human immunodeficiency virus protease that is now in phase three clinical trials. Association of the lack of phenotypic cross-resistance observed with Tipranavir with therapeutic response in phase II clinical trials;...

  • Tipranavir: A Viewpoint by Stefano Rusconi. Rusconi, Stefano // Drugs;2003, Vol. 63 Issue 15, p1619 

    Characterizes the protease inhibitor, Tipranavir. Efficacy of Tipranavir in treating human immunodeficiency virus-infected individuals; Uses of Tripanavir in the treatment of multi-protease inhibitor-treated patients who experience virological failure.

  • Tipranavir. Plosker, Greg L.; Figgitt, David P. // Drugs;2003, Vol. 63 Issue 15, p1611 

    â–´ Tipranavir is a potent and selective non-peptidic HIV-1 protease inhibitor with a markedly improved resistance profile compared with traditional, peptidomimetic protease inhibitors. â–´ The presence of five or fewer protease gene mutations or one or two protease inhibitor...

  • Yeni ve �nceden Tedavi Almis Akciger T�berk�lozlu Olgularda Ila� Diren�leri. K�m�rc�oglu, Berna; Senol, G�nes; Balci, G�nseli; Yalniz, Enver; �zden, Emel // Akciger Arsivi/Archives of Lung;Dec2007, Vol. 8 Issue 4, p117 

    Objective: This study was planned to determine the resistance rates against tuberculosis (TB) drugs in pulmonery tuberculosis patients in a ward of Izmir Chest Diseases and Surgery Researh Hospital. Data of 387 hospitalised male patients with active pulmonary tuberculosis between 1999-2004 were...

  • Turning the tables on TB. PAYNE, RICHARD // Chemistry in Australia;Oct2013, p16 

    The article offers information on the treatment of tuberculosis (TB) using drug comprising a combination therapy of four drugs (rifampicin, isoniazid, ethambutol and pyrazinamide) for six months, alongside observation of the treatment course by a medical professional. However, poor adherence to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics